CLAIMS

What is claimed is:

1. A composition for the treatment of wounds, said composition comprising the growth factors BMP-3 and TGF-ß2 in a pharmaceutically acceptable carrier.

2. The composition of claim 1, further comprising a growth factor selected from the group consisting of BMP-2, BMP-4, BMP-5, BMP-6, and BMP-7.

3. The composition of claim 2, further comprising a growth factor selected from the group consisting of FGF-1, TGF-ß1, and TGF-ß3.

4. The composition of claim 3, wherein the growth factors are derived from a natural source and are at least partially phosphorylated and glycosylated.

5. The composition of claim 1, excluding histone proteins H1c and H1x.

6. A composition for the treatment of wounds, said composition comprising a mixture of growth factors comprising BMP-2, BMP-3, BMP-6, and TGF-ß2 in a pharmaceutically acceptable carrier.

7. The composition of claim 6, from which ribosomal proteins LORP, L6, S20, L3, S3a, S4 and L32 have been substantially excluded.

8. The composition of claim 7, wherein the growth factors are derived from bovine bone and are at least partially phosphorylated and glycosylated.

9. A composition for the treatment of wounds, said composition comprising a mixture of proteins as identified in Figure 1, wherein the histone proteins have been excluded from the mixture, said mixture being in a pharmaceutically acceptable carrier.

10. The composition of claim 9, wherein the ribosomal proteins have been excluded therefrom.

11. A composition for the treatment of wounds, said composition comprising a mixture of proteins components as identified in Figure 1, wherein the ribosomal proteins have been excluded therefrom, said components being in a pharmaceutically acceptable carrier.

12. The composition of claim 11, wherein the histone proteins have been excluded therefrom.

13. A composition for the treatment of wounds, said composition comprising a mixture of proteins comprising BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, TGF-ß1, TGF-ß2, and TGF-ß2, and FGF-1 in a pharmaceutically acceptable carrier.

14. The composition of claim 13, wherein ribosomal proteins have been substantially eliminated from the mixture.

15. The composition of claim 13, wherein histone proteins have been substantially eliminated from the mixture.

16. The composition claim 13, wherein the components are isolated from a natural source and are at least partially phosphorylated and glycosylated.

17. The composition of claim 13, wherein at least one of the components is a recombinantly produced protein.

18. A method of wound healing, said method comprising applying a composition as in claims 13 to a wound.

19. The method of claim 18, where the pharmaceutically acceptable carrier includes a hydrogel.

20. The method of claim 18, wherein the components are isolated from a natural source and are at least partially phosphorylated and glycosylated.

21. The method of claim 18, where the pharmaceutically acceptable carrier includes a dressing selected from the group consisting of hydrocolloid dressings, hydrogels, foam dressings, and alginate dressings.

22. The method of claim 18, further including one or more active ingredient selected from the group consisting of arginine, glutamine, zinc, copper, vitamin C, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, and folate.

23. The method of claim 18, further including one or more growth factor selected from the group consisting of epidermal growth factor, platelet derived growth factor, insulin-like growth factor, keratinocyte growth factor, vascular endothelial growth factor, transforming growth factor alpha, nerve growth factor, connective tissue growth factor and granulocyte-monocyte colony stimulating factor.

24. The method of claim 11, further including one or more inflammation inhibitor selected from the group consisting of interleukin-1 inhibitor, interleukin-6 inhibitor and tumor necrosis factor-alpha inhibitor.